Patients deserve increased price transparency and affordable care, particularly as the system shifts significant costs to them. — Heather Bresch Copy Share Image
“UBS increased its price target on Gilead to $125 from $115, Achillion to $15 from $11, Regeneron to $360 from $320 and Amgen to $155 from $129.” — Anonymous Copy Share Image
